Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

23.09
+0.48002.12%
Volume:195.93K
Turnover:4.48M
Market Cap:1.68B
PE:-38.18
High:23.11
Open:22.68
Low:22.54
Close:22.61
Loading ...

Kiniksa : Has Exercised Its Right to Terminate Its Exclusive License Agreement for Mavrilimumab With Medimmune

THOMSON REUTERS
·
25 Feb

Kiniksa Pharmaceuticals International Plc: to Discontinue Abiprubart Development in SjÖGren's Disease

THOMSON REUTERS
·
25 Feb

Kiniksa Pharmaceuticals International Plc - Arcalyst 2025 Net Product Revenue Expected $560-$580 Million

THOMSON REUTERS
·
25 Feb

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

GlobeNewswire
·
25 Feb

Evercore ISI Reaffirms Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)

TIPRANKS
·
04 Feb

Exploring High Growth Tech Stocks in the United States

Simply Wall St.
·
29 Jan

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

Zacks
·
14 Jan

Kiniksa Pharmaceuticals Reports Preliminary Q4 And FY2024 Arcalyst Net Product Revenue Of $121.9M And $416.4M, Respectively

Benzinga
·
13 Jan

Kiniksa Pharmaceuticals International - Arcalyst 2025 Net Product Revenue Expected $560-$580 Million

THOMSON REUTERS
·
13 Jan

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

GlobeNewswire
·
13 Jan

Kiniksa Pharmaceuticals (KNSA) Gets a Buy from Jefferies

TIPRANKS
·
05 Jan

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.
·
20 Dec 2024

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

GlobeNewswire
·
27 Nov 2024

Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?

Insider Monkey
·
13 Nov 2024

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

GlobeNewswire
·
13 Nov 2024

Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
06 Nov 2024